Ocular Physiological Phenomena

9 trials 4 recruiting

Filter these 9 trials by phase, country and sponsor.

Open in Search →

IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR’S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE META… Not authorised

2023-506686-66-00 HLA-A2 negative metastatic uveal melanoma 10
Study to Assess the Ability of ONL1204 to Slow the Progression of Atrophic Age-related Macular Degeneration Recruiting

2024-513174-22-00 Atrophic Age-related Macular Degeneration (AMD) 4 2026-04-14
Brimonidine eye drops in the prevention of myopia progression Recruiting

2025-521878-33-00 Myopia 4 2025-12-10
Comparison of topical hydrocortisone versus dexamethasone treatment for inflammatory secretions of the conjunctiva in patients with ocular p… Recruiting

2024-517441-14-00 inflammatory secretions of the conjunctiva (Eye desease 11 2024-10-30
IDE196 (Darovasertib) in Combination with Crizotinib as First-line Therapy in Metastatic Uveal Melanoma Recruiting

2023-506686-66-01 HLA-A2 negative metastatic uveal melanoma 10 2024-10-09
Glaucoma Intensity Treatment Study – Intensive non-invasive glaucoma treatment vs conventional stepwise treatment – a prospective, randomize… Ended

2023-510041-16-00 Glaucoma, open-angle and PEX glaucoma 6 2013-04-22
Phase 2a, Random, double masked, Placebo-controlled, side by side group, multiple center study evaluating the effectiveness and safety of ST… Ended

2024-517104-11-00 Fuchs Endothelial Corneal Dystrophy (FECD) 4 2023-06-08
A Phase 2/3 Double-masked, Randomized, 2-stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic M… Ended

2023-507208-30-00 Diabetic Macular Edema (DME) 10 2022-09-20
A Phase 3 Double-masked, Randomized, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edem… Ended

2023-507207-66-00 Diabetic Macular Edema (DME) 5